Literature DB >> 17026795

Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.

Muhammad Wasif Saif1, James Merritt, Joan Robbins, Jeffrey Stewart, Joachim Schupp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17026795     DOI： 10.3816/CCC.2006.n.042

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN： 1533-0028            Impact factor:   4.481


× No keyword cloud information.
  3 in total

Review 1.  Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.

Authors:  Susan E Pories; Gerburg M Wulf
Journal:  Breast Cancer (Dove Med Press)       Date:  2010-06-21

2.  Brain microischemic phenomena in a woman receiving bevacizumab treatment: a case report.

Authors:  Carlo C Quattrocchi; Andrea M Alexandre; Giuseppe Tonini; Yuri Errante; Rosario F Grasso; Bruno Beomonte Zobel
Journal:  J Med Case Rep       Date:  2011-02-27

3.  Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.

Authors:  Girolamo Ranieri; Cristina Ferrari; Alessandra Di Palo; Ilaria Marech; Mariangela Porcelli; Gianmarco Falagario; Fabiana Ritrovato; Luigi Ramunni; Margherita Fanelli; Giuseppe Rubini; Cosmo Damiano Gadaleta
Journal:  Int J Mol Sci       Date:  2017-07-06       Impact factor: 5.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.